The development of allogeneic cell therapies continues to gain momentum, with 293 allogeneic clinical trials ongoing worldwide, treating a wide range of indications! * They show blockbuster potential rivalling the autologous approach with improved accessibility, cost efficiency, and manufacturing timelines. Given these fundamental advantages, the field continues to prioritize the development of allogeneic advances to provide accessible therapies for patients globally.
Dedicated to accelerating clinical translation, the Allogeneic Cell Therapies Summit is the leading industry-focused meeting promising unrivalled content for all, whether you are leading an allogeneic start up or a well-versed company looking towards commercialization.
While the commercial potential for successful off-the-shelf therapies is unmatched, there are still a minefield of questions yet to be answered…
• Is gene engineering the only way forward and is it safe?
• What is the best strategy to scale up manufacturing?
• Does cryopreservation really affect the therapies efficacy?
• How can we develop a truly off-the-shelf approach?
Two years since we last met in person, we are excited and eager to once again bring together the biggest community of thought leaders and experts within the allogeneic cell therapy space. Uniting 400+ key decision makers at the forefront of off-the-shelf development, our four-day, four tracked meeting will cover all aspects of drug development from pre-clinical, translational, and clinical work, all the way through to manufacturing, supply and storage, making this your one stop shop for all things allogeneic!
*Data sourced from Beacon Targeted Therapies, January 2022
https://allogeneic-cell-therapies.com/
9-12 May, 2022
Boston, MA
Contact:
info@hansonwade.com
Speakers: Blake Aftab, CSO, Adicet Bio, Joanna Brewer, SVP Allogeneic Research, Adaptimmune, Barbra Sasu, CSO, Allogene, Pascal Touchon, President & CEO, Atara Biotherapeutics, Carrie Brownstein, CMO, Cellectis, Brian Culley, CEO, Lineage Cell Therapeutics, Silviu Itescu, CEO, Mesoblast, Gary Lee, CSO, Senti Bio
Schedule:
Time: 8:30 AM - 5:30 PM